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Abstract
Background: Antiretroviral therapy (ART) requires high-level (> 95%) adherence. Kenya is rolling out ART access
programmes and, issue of adherence to therapy is therefore imperative. However, published data on adherence to
ART in Kenya is limited. This study assessed adherence to ART and identified factors responsible for non adherence
in Nairobi.
Methods: This is a multiple facility-based cross-sectional study, where 416 patients aged over 18 years were
systematically selected and interviewed using a structured questionnaire about their experience taking ART.
Additional data was extracted from hospital records. Patients were grouped into adherent and non-adherent based
on a composite score derived from a three questions adherence tool developed by Center for Adherence Support
Evaluation (CASE). Multivariate regression model was used to determine predictors of non-adherence.
Results: Overall, 403 patients responded; 35% males and 65% females, 18% were non-adherent, and main (38%)
reason for missing therapy were being busy and forgetting. Accessing ART in a clinic within walking distance from
home (OR = 2.387, CI.95 = 1.155-4.931; p = 0.019) and difficulty with dosing schedule (OR = 2.310, CI.95 = 1.211-
4.408, p = 0.011) predicted non-adherence.
Conclusions: The study found better adherence to HAART in Nairobi compared to previous studies in Kenya.
However, this can be improved further by employing fitting strategies to improve patients’ ability to fit therapy in
own lifestyle and cue-dose training to impact forgetfulness. Further work to determine why patients accessing
therapy from ARV clinics within walking distance from their residence did not adhere is recommended.
Background
Antiretroviral treatment success depends on sustainable
high rates of adherence to medication regimen of ART
[1]. However, significant proportions of HIV-infected
patients do not reach high levels of adherence and this
can lead to devastating public health problems. Mills et
al in a meta-analysis study found a combined continen-
tal adherence to ART of 64% with 55% adherence in
North America and 77% in Africa. Twenty four percent
non-adherence has been reported in Southwest Ethiopia
[2], 22% in Cote d’Ivore [3] and 13% in Cameroon [4].
Byakika et al [5] reported 68% adherence to HIV treat-
ment in Uganda, 54% in Nigeria [6] and 63% in South
Africa [7]. Non-adherence to ART has been associated
to diverse factors including patient related factors,
health condition/disease, health care system and health-
care teams, therapy/treatment and Socio-economic fac-
tors [5,6,8-10]. Kenya is rolling out a free HAART
programme to increase access and by 2009, 336980
patients were accessing [11], and adherence reported
vary from 48% in Kibera, Nairobi [12]; 56.8% in Eldoret
[13] and 64% in Mombasa [14].
Statement of the research hypothesis
Published data about factors that influence non-adher-
ence to ART in Kenya is limited. To generate this
knowledge, this study determined prevalence of non-
adherence and associated factors.
It was hypothesized that:
H0 - there are no factors association with non-adher-
ence to HAART among HIV patients in Nairobi, Kenya.
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Method
Setting
This study was conducted at HIV/AIDS treatment cen-
tre in the Kenyatta National Hospital, Kenya Medical
Research Institute (KEMRI) and Riruta Health centre in
Nairobi, Kenya.
Population sample
The sample was of 416 HIV+ outpatients aged 18 years
or more on free HAART for three or more months
between November, 2008 and April, 2009.
Design
Cross-sectional observational study design collected data
from systematically selected patients as they visited the
three purposively selected HIV clinics to refill. The
patients were interviewed about their health beliefs,
health system interaction, ARV therapy uptake and rea-
sons for non-adherence. CASE adherence tool [15] was
used to determine adherence. Additional data about
time on ARV and age were extracted from hospital
records.
CASE Adherence tool was developed by the New York
Academy of Medicine’s (NYAM) Center for Adherence
Support Evaluation (CASE). It consists of three adher-
ence questions: (rated on a likert scale) “How often do
you feel that you have difficulty taking your HIV medi-
cations on time? On average, how many days PER
WEEK would you say that you missed at least one dose
of your HIV medications? When was the last time you
missed at least one dose of your HIV medications?"A
higher composite score signify better adherence.
The CASE Adherence Index correlated strongly with
the AACTG three-day self-reported adherence data (p <
0.001), is more strongly associated with HIV outcomes
and performed as well as the three-day self-report when
predicting CD4 cell count status[16].
Data analysis
Patient’s scores in the CASE adherence tool were
summed up to obtain a composite score that ranged
from 3 to 16 points. Patients with Index score ≤10
points were classified as non-adherent and > 10 adher-
ent [15]. Other data generated from the questionnaire
were keyed into SPSS and analyzed for frequencies,
cross-tabulations, chi-square test, and multivariate logis-
tic regression to determine predicting factors. A p-value
< 0.05 was considered significant in all statistical
analysis.
Ethical considerations
Ethical clearance was given by the KEMRI’s National
Ethical Review Committee, and permission to conduct
the research was obtained from the participating clinics.
Consent was obtained both verbally and in writing in
either English or Kiswahili. To ensure confidentiality,
interviews were conducted in private and strict control
maintained over data.
Results
Characteristics of the respondents
Characteristics of the respondents are presented in
Table 1. Out of the 416 patients interviewed, 403
answered all adherence questions and were analyzed.
Females were 262 (65%) and males 141 (35%); their age
ranged between 18 and 64 years old. Most patients were
married 213 (53%); 246 (61%) had at least secondary
education, 145 (36%) had primary education and 10
(3%) had no formal education. Three hundred (75%)
respondents earned less than $120 per month; and most
271(67%) lived in 1-3 rooms and the rest in a more
than 1 bedroom house.
Majority respondents 281 (70%) had a CD4 count of
more than 200 cells/ml, 280 (80%) had more than 1
year experience with ART and 138(43%) had not had
side effects. ART knowledge was extremely high (100),
but only 197 (49%) stated condom use as important,
(82%) reported adherence and (68%) nutrition.
Most 321(80%) patients lived with family, 329(82%)
had disclosed their HIV status and 282(79%) reported
getting social support. Sixty nine (17%) patients found
therapy disruptive of their life while 186 (46%) were
embarrassed taking ARV. Most respondents 154 (38%)
reported being busy and forgetting as the reason for
missing therapy, while 197 (49%) had never failed to
take medicine.
Adherence to HAART
Seventy two (18%) respondents were non-adherence
based on CASE adherence method, while74 (18%)
reported missing at least one dose of therapy per week
(< 95% adherence) (Table 2). Adherence to HAART
among respondents differed significantly at p-value <
0.05 by age (p = 0.017), difficulty fitting therapy in
own daily schedule (p = 0.006), social support (p =
0.015), period on therapy (p = 0.002), self report
missed therapy (p = 0.001), proximity to clinic where
respondents refilled (p = 0.003) and time spent at
clinic per visit (p = 0.000) by univariate analysis (Table
1). However, only having difficult fitting therapy in
own schedule (OR = 2.310, CI.95 = 1.211-4.408, p =
0.011) and proximity to clinic where respondents
refilled (OR = 2.387, CI.95 = 1.155-4.931, p = 0.019)
predicted non-adherence by multivariate analysis
(Table 3). Main reason for missing therapy was being
busy and forgetting.
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Table 1 Characteristics of respondents
Characteristics Adherent p-value
Variable No; n (%) Total; n (%)
Socio-demographic characteristics
Gender distribution
All 72 (18) 331 (82) 403 (100)
Males 25 (18) 116 (82) 141 (35) 0.958
Females 47 (18) 215 (82) 262 (65)
Mean age
All 37.6 yrs 40.2 yrs 39.7 yrs 0.017*
Male 41.6 yrs 42.8 yrs 42.6 yrs 0.491
Female 35.4 yrs 38.8 yrs 38.2 yrs 0.012*
Marital status 0.225
Never married 14 (19) 58 (81) 72 (18)
Married 40 (19) 173 (81) 213 (53)
Divorced/Separate 13 (23) 44 (77) 57 (14)
Widowed 5 (9) 52 (91) 57 (14)
Missing 0 4 4 (1)
Ever widowed? 0.053
Yes 5 (9) 52 (91) 57 (14)
No 67 (20) 275 (80) 342 (85)
Education level 0.665
No education 1 (10) 9 (10) 10 (3)
Primary 28 (19) 117 (81) 145(36)
Secondary 32 (16) 168 (84) 200(50)
Post secondary 10 (22) 36 (78) 46 (11)
Missing 2
Monthly Income (USD) 0.734
Unemployed 27 (20) 110 (80) 137(34)
< 60 17 (21) 66 (80) 83 (21)
61 - 120 11 (14) 69 (86) 80 (20)
121 - 180 2 (9) 21 (91) 23 (6)
181 - 240 5 (19) 22 (82) 27 (7)
241 - 600 5 (15) 29 (85) 34 (8)
600+ 4 (24) 13 (77) 17 (4)
Missing 2
Housing 0.275
1 room 39 (21) 147 (79) 186(46)
2-3 rooms 16 (19) 69 (81) 85 (21)
1 bedroom 7 (17) 34 (83) 41 (10)
2 bedrooms 4 (8) 48 (92) 52 (13)
≥ 3 bedrooms 6 (15) 33 (85) 39 (10)
1-3 rooms 55 (20) 216 (80) 271 (67) 0.068
≥ 1 bedrooms 17 (13) 115 (87) 132 (33)
Clinical characteristics
CD4 cell count ≤200 cells/ml 0.025*
Yes 25(26) 71 (74) 96 (24)
No 44(16) 237(84) 281(70)
Missing 26 (6)
Time on ART 0.003*
3 to 6 months 13(37) 22 (63) 35 (9)
6 - 12 months 18(21) 69 (79) 87 (22)
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Table 1 Characteristics of respondents (Continued)
1 to 2 years 25(19) 110(81) 135(34)
3 years + 16(11) 129(89) 145(36)
Missing 1
Adverse effects
Nausea 7 (30) 16 (70) 23 (7) 0.898
Vomiting 1 (8) 11 (92) 12 (4)
Diarrhea 3 (23) 10 (77) 13 (4)
Neuropathy 3 (10) 27 (90) 30 (9)
Itching 6 (23) 20 (77) 26 (8)
Rashes 5 (12) 36 (88) 41 (13)
Others 6 (15) 33 (85) 39 (12)
None 24(17) 114(83) 138(43)
ART knowledge
Health literacy
Adhere 57 (17) 272 (83) 329 (82) 0.55
Condom use 35 (18) 162 (82) 197 (49) 0.959
Nutrition 43 (16) 233 (84) 276 (68) 0.077
Use
Identify drugs 72 (18) 331 (82) 403 (100)
Dosage 72 (18) 330 (82) 402 (100)
Life-long therapy 72 (18) 328 (82) 400 (99)
Social support
Living with 0.484
Family 53(17) 268(83) 321(80)
Friends 2 (22) 7 (78) 9 (2)
Alone 16(22) 56 (78) 72 (18)
Living with children? 0.345
No 10(14) 62 (86) 72 (18)
Yes 50(18) 235(82) 285(71)
Have no children 12(26) 34 (74) 46 (11) 0.122
Has children 60(17) 297(83) 357(89)
HIV Status disclosed 0.794
Yes: 58(18) 271(82) 329(82)
No: 13(18) 60 (81) 73 (18)
Reminded dose by 0.781
Self 36(19) 151(81) 187(46)
Family 35(17) 176(83) 211(52)
Friends 1 (20) 4 (80) 5 (1)
Level of social Support
Never (0%) 13(23) 43 (77) 56 (14)
Rarely (25%) 5 (28) 13 (72) 18 (5)
Sometimes (50%) 12(26) 34 (74) 46 (11)
Often (75%) 17(22) 60 (78) 77 (19)
Always (> 75%) 24(18) 181(88) 205(51)
Missing 1
Felt social Support 0.030*
< Sometimes 18(24) 56 (76) 74 (21)
> Sometimes 41(14) 241(86) 282(79)
Concerns about therapy
Taking ART worries me 0.378
Agree 16 (22) 58 (78) 74 (18)
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Discussion
The current study assessed non-adherence and factors
associated with it in Nairobi, Kenya. Prevalence of non-
adherence found in this study (18%) is comparable to
the continental prevalence (23%) for Africa [1], 21% in
Southwest Ethiopia [2] and 22% in Cote d’Ivore [3]. But,
inconsistent with the findings of Ellis et al. in Kibera,
Nairobi (48%) [12]; Talam et al. in Eldoret (56.8%) [13]
and Munyao et al. in Mombasa [14]. The inconsistency
with the findings of Eldoret study was attributed to dif-
ferences in assessment methods, and inconsistency with
the findings of Kibera and Mombasa studies to differ-
ence in treatment periods (2005) when ART knowledge
among patients and clinicians was low [17].
In this study, younger respondents below the mean
age (39.7 years) were more likely not to adhere to
HAART although age did not predict. The finding is
consistent with the findings of Iliyasu et al in Nigeria
[6], Carballo et al in Spain [9] and Orrell et al in
South Africa [7] but, inconsistent with the finding of
Talam et al in Eldoret [13]. The inconsistent with
Eldoret study can be attributed to difference in mean
age; respondents in the Eldoret study were younger
(mean age 36.1 years). Better adherence among older
adults may be explained by survivor effect in that, indi-
viduals who maintain greater compliance with treat-
ment recommendations may actually outlive those who
are non-adherent. Proportion of female in this study
was two-fold that of male and is similar to the propor-
tion of HIV/AIDS reported in Kenya [18]. However,
gender did not predict non-adherence to HAART in
Nairobi. These findings correlated with findings of
other studies [5,6,13,19]. Marital status did not predict
non-adherence. Other studies have reported mixed
results; Byakika et al found an association between
marital status and non-adherence to ARV therapy in
Uganda [5] while, Weiser et al in Botswana did not
[19].
Table 1 Characteristics of respondents (Continued)
Disagree 55 (17) 264 (83) 319 (79)
Not sure 10 (3)
I Worry about long-term effects of ART 0.885
Agree 31 (19) 135 (81) 166 (41)
Disagree 40 (18) 181 (82) 221 (55)
Not sure 16 (4)
Lack understanding of how ART works 0.505
Agree 28 (20) 115 (80) 143 (35)
Disagree 40 (17) 197 (83) 237 (59)
Not sure 23 (6)
Therapy disrupt my life 0.006*
Agree 20 (29) 49 (71) 69 (17)
Disagree 49 (15) 274 (85) 323 (80)
Not sure 11 (3)
I am embarrassed taking ARV 0.162
Agree 38 (20) 148 (80) 186 (46)
Disagree 31 (15) 175 (85) 206 (51)
Not sure 11 (3)
Reason for not taking therapy
Implied missed therapy 0.001*
Gave reason for not taking 50 (24) 156 (76) 206 (51)
Never failed 22 (11) 175 (89) 197 (49)
Reason for not taking medicine 0.000*
Being busy and forgetting 44 (29) 110 (71) 154 (38)
Hiding from colleagues 3 (60) 2 (40) 5 (2)
Others 3 (6) 44 (94) 47 (11)
*Statistically significant at level p < 0.05 by chi-square test
Table 2 Prevalence of non-adherence to HAART among
respondents
Adherent?




a)CASE adherence Index; i.e. ≤ 10 (non-adherent) 72 (18) 331 (82)
b)missed at least once a week method (< 95
adherence)
74 (18) 329 (82)
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Socio-economic factors did not significantly influence
adherence in this study. Findings with respect to income
were consistent with the findings of Orrell et al in
South Africa [7] but inconsistent with findings of Bya-
kika et al in Uganda where patients paid for ART [5].
Finding about formal education was consistent with the
findings of Weiser et al in Botswana [19] but, inconsis-
tent with the findings of Carballo et al in Spain [9]
where understanding of treatment regimen was poor
[10]. Although respondents living in smaller houses
were more likely not to adhere to therapy than respon-
dents living in bigger houses, house size did not predict
non-adherence. These findings are consistent with find-
ings in other studies [9,20].
In this study, proximity to clinic predicted non-adher-
ence. Respondents who accessed therapy in clinics
within a walking distance from their homes were about
two and a half times more likely not to adhere than
patients who refilled in far away clinics. These findings
together with social stigma associated with ART use
suggested that most respondents who accessed free ther-
apy in clinics within walking distance to their homes did
so due to lack of choice; speculatively, could not afford
transport cost to alternative HAART clinics. Where
respondents paid for transport, amounts paid did not
significantly influence non-adherence to HAART which
was consistent with the finding of Byakika et al in
Uganda [5]. Most respondents reported felt social sup-
port from friends and relatives, and it was therefore
hypothesized that these friends and relatives also pro-
vided respondents with material support, making it pos-
sible to overcome cost barrier that has been associated
with non-adherence to therapy in other studies [5].
Such “helpers” have been found to make their expecta-
tions for the patients to adherence known, thus, creating
a responsibility on the part of patients who conse-
quently, adhered to therapy to promote goodwill with
the helpers [21]. Recipients who reported receiving
social support were two folds more likely to adhere to
therapy than those who did not. These findings are con-
sistent with many ARV therapy adherence studies
[16,2,22-25].
Adherence to therapy in this study increased with
duration on HAART although did not predict it. This is
consistent with findings of Mannheimer et al [15] but,
inconsistent with the findings of Byakika et al in Uganda
[5]. The inconsistency was attributed to the shorter
experience with ARVs and paying for therapy in the
Uganda study. Where drugs are paid for, many studies
have found shortage of drugs due to economic barriers,
as the most common reason for non adherence. The
reported adverse effects did not significantly influence
non-adherence which was consistent with findings of
Weiser et al in Botswana [19], and Aspeling and Van
Wyk in South Africa [22]. The findings could be attribu-
ted to high ART knowledge and awareness found
among respondents in line with the South Africa study
in which informed HIV patients tolerated side effects
and adhered to therapy [22].
In this study, respondents regarded adherence to
HAART extremely important to HIV treatment and
translated this knowledge into positive belief about
necessity of HIV medication almost universally. Belief
in the benefit of therapy found together with availabil-
ity of free HAART is credited for improved adherence
among the respondents. This finding correlates with
findings of Aspeling and Van Wyk in South Africa
where adequate pre-therapy counselling and HIV edu-
cation impacted adherence positively [22]. However,
giving reason for skipping therapy predicted non-
adherence. Three quarters of the respondents who
gave reasons for skipping therapy stated being busy
and forgetting as the reason and a third of them did
not adhere. This finding is consistent with findings of
Nieuwkerk et al [26] and Byakika et al in Uganda [5].
Having difficult fitting therapy in own daily schedule
predicted non-adherence. Respondents who reported
difficult with therapy were more than two folds more
likely not to adhere to ARV therapy. This was consis-
tent with the findings of Munro et al [8]. It was specu-
lated, in line with Vervoort et al [24] finding that when
medication scheme did not fit in a patient’s routine, it
caused them to forget to take medications and conse-
quently resulted in poor adherence.
Table 3 Predictors of Non-adherence to HAART among respondents
Crude Adjusted
Characteristics OR (CI.95) p-value OR (CI.95) p-value
Proximity to clinic where refilled 2.740 (1.382,5.434) 0.003* 2.387
(1.155,4.931)
0.019**










**Statistically significant at level p < 0.05 by multivariate analysis
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Conclusion
Given the complex array of factors associated with non-
adherence, no single strategy is likely to be effective for
every patient. It is recommended that patients be tar-
geted with comprehensive individualized interventions
employing behavioral educational strategies to improve
ability to fit therapy in own lifestyle and cue-dose train-
ing to impact forgetfulness. Further research is recom-
mended to explain poor adherence among patients
accessing therapy from ARV clinics within walking dis-
tance from their homes.
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